Literature DB >> 1730113

The indications for elective treatment of the neck in cancer of the major salivary glands.

J G Armstrong1, L B Harrison, H T Thaler, H Friedlander-Klar, D E Fass, M J Zelefsky, J P Shah, E W Strong, R H Spiro.   

Abstract

To define the indications for elective neck treatment, the cases of 474 previously untreated patients were reviewed who had locally confined major salivary gland cancers treated between 1939 and 1982. Clinically positive nodes were present in 14% (67 of 474). Overall, clinically occult, pathologically positive nodes occurred in 12% (47 of 407). By univariate analysis, several factors appeared to predict the risk of occult metastases; however, multivariate analysis revealed that only size and grade were significant risk factors. Tumors 4 cm or more in size had a 20% (32 of 164) risk of occult metastases compared with a 4% (nine of 220) risk for smaller tumors (P less than 0.00001). High-grade tumors (regardless of histologic type) had a 49% (29 of 59) risk of occult metastases compared with a 7% (15 of 221) risk for intermediate-grade or low-grade tumors (P less than 0.00001). In view of the low frequency of occult metastases in the entire group, routine elective treatment of the neck is not recommended. High-grade tumors and larger tumors have a high rate of occult neck metastases, and treatment should be considered in this group.

Entities:  

Mesh:

Year:  1992        PMID: 1730113     DOI: 10.1002/1097-0142(19920201)69:3<615::aid-cncr2820690303>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  51 in total

1.  Management of malignant parotid tumors.

Authors:  Nikolaos Papadogeorgakis; Lampros Goutzanis; Vassilis Petsinis; Constantinos Alexandridis
Journal:  Oral Maxillofac Surg       Date:  2011-01-05

2.  [On the diagnosis and treatment of parotid gland tumors. Results of a nationwide survey of ENT hospitals in Germany].

Authors:  S F Preuss; O Guntinas-Lichius
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

3.  The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study.

Authors:  R Alex Harbison; Alan J Gray; Ted Westling; Marco Carone; Cristina P Rodriguez; Neal D Futran; Richard B Cannon; Jeffrey Houlton
Journal:  Laryngoscope       Date:  2019-08-29       Impact factor: 3.325

4.  Occurrence of lymph node metastasis in early-stage parotid gland cancer.

Authors:  Markus Stenner; Christoph Molls; Jan C Luers; Dirk Beutner; Jens P Klussmann; Karl-Bernd Huettenbrink
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-14       Impact factor: 2.503

Review 5.  Salivary mucoepidermoid carcinoma revisited.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Alessandra Rinaldo; Primož Strojan; Missak Haigentz; William M Mendenhall; Robert P Takes; Vincent Vander Poorten; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-26       Impact factor: 2.503

6.  [Treatment of salivary gland malignancies].

Authors:  Michael Formanek
Journal:  Wien Med Wochenschr       Date:  2008

7.  The Milan system for reporting salivary gland cytopathology: The clinical impact so far. Considerations from theory to practice.

Authors:  Esther Diana Rossi; William C Faquin
Journal:  Cytopathology       Date:  2020-05       Impact factor: 2.073

Review 8.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

9.  Development of a novel salivary gland cancer lymph node staging system.

Authors:  Katri Aro; Allen S Ho; Michael Luu; Sungjin Kim; Mourad Tighiouart; Jon Mallen-St Clair; Emi J Yoshida; Stephen L Shiao; Ilmo Leivo; Zachary S Zumsteg
Journal:  Cancer       Date:  2018-05-09       Impact factor: 6.860

10.  Treatment Results of Major Salivary Gland Cancer by Surgery with or without Postoperative Radiation Therapy.

Authors:  Jae Myoung Noh; Yong Chan Ahn; Heerim Nam; Won Park; Chung-Hwan Baek; Young-Ik Son; Han-Sin Jeong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-06-30       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.